Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500
Buy Report View Sample

Published: October 31, 2022 Report Code: GDGMDHC22190TDB-ST

Select Item

Metabotropic glutamate receptor 2 (MGLUR2) is a receptor for glutamate. The ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase.

The MGLUR2 pipeline market research report provides comprehensive information on the MGLUR2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research, and development history as well as the latest news and press releases. Additionally, the report provides an overview of key players involved in MGLUR2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects.

MGLUR2 Pipeline Products Market Segmentation by Therapy Areas

The key therapy area in the MGLUR2 pipeline products market is central nervous system.

MGLUR2 Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the MGLUR2 pipeline products market are Metabotropic Glutamate Receptor 2 Agonist and Metabotropic Glutamate Receptor 2 Antagonist.

MGLUR2 Pipeline Products Market Analysis by Mechanisms of Action, 2022 (%)

MGLUR2 Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the MGLUR2 pipeline products market, download a free report sample

MGLUR2 Pipeline Products Market Segmentation by Routes of Administration

The key route of administration in the MGLUR2 pipeline products market is oral.

MGLUR2 Pipeline Products Market Segmentation by Molecule Types

The key molecule type in the MGLUR2 pipeline products market is small molecule.

MGLUR2 Pipeline Products Market - Competitive Landscape

The leading players in the MGLUR2 pipeline products market are Addex Therapeutics Ltd, Bristol-Myers Squibb Co, Camino Pharma LLC, Denovo Biopharma LLC, Eli Lilly and Co, Johnson & Johnson, Merck & Co Inc, Noema Pharma AG, Sumitomo Pharma Co Ltd, and Taisho Pharmaceutical Holdings Co Ltd.

MGLUR2 Pipeline Products Market Analysis by Companies, 2022 (%)

MGLUR2 Pipeline Products Market Analysis by Companies

To know more about leading players in the MGLUR2 pipeline products market, download a free report sample

MGLUR2 Pipeline Products Market Report Overview

Key Therapy Areas Central Nervous System
Key Mechanisms of Action Metabotropic Glutamate Receptor 2 Agonist and Metabotropic Glutamate Receptor 2 Antagonist
Key Routes of Administration Oral
Key Molecule Type Small Molecule
Leading players Addex Therapeutics Ltd, Bristol-Myers Squibb Co, Camino Pharma LLC, Denovo Biopharma LLC, Eli Lilly and Co, Johnson & Johnson, Merck & Co Inc, Noema Pharma AG, Sumitomo Pharma Co Ltd, and Taisho Pharmaceutical Holdings Co Ltd

Segments Covered in the Report

MGLUR2 Pipeline Products Market Therapy Areas Outlook

  • Central Nervous System

MGLUR2 Pipeline Products Market Routes of Administration Outlook

  • Oral

MGLUR2 Pipeline Products Market Mechanisms of Action Outlook

  • Metabotropic Glutamate Receptor 2 Agonist
  • Metabotropic Glutamate Receptor 2 Antagonist

MGLUR2 Pipeline Products Market Molecule Type Outlook

  • Small Molecule

Scope

  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)

  • The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which include, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities

  • The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews the latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage

  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Addex Therapeutics Ltd
Bristol-Myers Squibb Co
Camino Pharma LLC
Denovo Biopharma LLC
Eli Lilly and Co
Johnson & Johnson
Merck & Co Inc
Noema Pharma AG
Sumitomo Pharma Co Ltd
Taisho Pharmaceutical Holdings Co Ltd

Table of Contents

  • 1. Table of Contents

    • 1.1. List of Tables

    • 1.2. List of Figures

  • 2. Introduction

    • 2.1. Global Markets Direct Report Coverage

  • 3. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Overview

  • 4. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Therapeutics Development

    • 4.1. Products under Development by Stage of Development

    • 4.2. Products under Development by Therapy Area

    • 4.3. Products under Development by Indication

    • 4.4. Products under Development by Companies

    • 4.5. Products under Development by Universities/Institutes

  • 5. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Therapeutics Assessment

    • 5.1. Assessment by Mechanism of Action

    • 5.2. Assessment by Route of Administration

    • 5.3. Assessment by Molecule Type

  • 6. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Companies Involved in Therapeutics Development

    • 6.1. Addex Therapeutics Ltd

    • 6.2. Bristol-Myers Squibb Co

    • 6.3. Camino Pharma LLC

    • 6.4. Denovo Biopharma LLC

    • 6.5. Eli Lilly and Co

    • 6.6. Johnson & Johnson

    • 6.7. Merck & Co Inc

    • 6.8. Noema Pharma AG

    • 6.9. Sumitomo Pharma Co Ltd

    • 6.10. Taisho Pharmaceutical Holdings Co Ltd

  • 7. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Drug Profiles

    • 7.1. BMT-133218 – Drug Profile

    • 7.2. DSP-3456 – Drug Profile

    • 7.3. JNJ-1813 – Drug Profile

    • 7.4. LY-3020371 – Drug Profile

    • 7.5. mGlu2 NAM – Drug Profile

    • 7.6. NOE-109 – Drug Profile

    • 7.7. pomaglumetad methionil – Drug Profile

    • 7.8. SBP-0069330 – Drug Profile

    • 7.9. SBP-9881 – Drug Profile

    • 7.10. Small Molecule to Agonize Metabotropic Glutamate Receptor 2 for Psychosis – Drug Profile

    • 7.11. Small Molecules to Antagonize mGlu2 for Anxiety and Depression – Drug Profile

    • 7.12. TS-134 – Drug Profile

    • 7.13. TS-161 – Drug Profile

  • 8. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Dormant Products

  • 9. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Discontinued Products

  • 10. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Product Development Milestones

  • 11. Featured News & Press Releases

    • 11.1. Nov 15, 2021: Addex strategic partner successfully completes Phase 1 in Japan with ADX71149

    • 11.2. Aug 25, 2021: Camino Pharma initiates phase 1 study of SBP-9330 in development for the treatment of tobacco use disorder

    • 11.3. Jul 01, 2021: Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators

    • 11.4. Jun 07, 2021: Addex starts phase 2 clinical study of ADX71149 for epilepsy

    • 11.5. Jan 21, 2021: Addex ADX71149 receives IND approval to start a phase 2a clinical study in epilepsy

    • 11.6. Sep 16, 2020: $11.4 million NIH grant advances drug to treat nicotine addiction

    • 11.7. Jun 30, 2020: Camino Pharma receives $920K Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health

    • 11.8. Jun 16, 2020: Addex mGlu2 PAM program to advance into Epilepsy Phase 2a proof of concept clinical study

    • 11.9. Oct 02, 2018: Addex selective mGlu2 PAM ADX71149 included in review highlighting promising investigative drugs for epilepsy

    • 11.10. Sep 04, 2018: Addex’s selective mGlu2 PAM ADX71149 shows promise in treating severe panic disorders and PTSD

    • 11.11. Feb 27, 2017: Addex’s ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia

    • 11.12. Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy

    • 11.13. Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms

    • 11.14. Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression

    • 11.15. Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients

  • 12. Appendix

    • 12.1. Methodology

    • 12.2. Coverage

    • 12.3. Secondary Research

    • 12.4. Primary Research

    • 12.5. Expert Panel Validation

    • 12.6. Contact Us

    • 12.7. Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Addex Therapeutics Ltd, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Camino Pharma LLC, 2022

Pipeline by Denovo Biopharma LLC, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by Johnson & Johnson, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by Noema Pharma AG, 2022

Pipeline by Sumitomo Pharma Co Ltd, 2022

Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Frequently asked questions

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$3,500

Can be used by individual purchaser only

Most Popular
$7,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Other Diseases reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more